TD Cowen on Day One Biopharmaceuticals (DAWN): 'Focused Approach Could Lead to Double-Digit Growth'
Tweet Send to a Friend
TD Cowen analyst Tara Bancroft reiterated a Buy rating and $34.00 price target on Day One Biopharmaceuticals (NASDAQ: DAWN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
